Publications

The 'Holy Grail' for Health Systems Modelling: Hybrid Simulation for Strengthened Evaluation of Complex Interventions.

CASSIDY, R; Alibrahim, A; FOSS, A; Semwanga, AR; Mziray, N; Binyaruka, P; BORGHI, J;

2023

. Abstract accepted for oral presentation (2023).

Using agent-based modelling to inform incentive design across three levels of care in the payment for performance (P4P) scheme for childbirth care in Tanzania.

Alibrahim, A; FOSS, A; Mziray, N; Binyaruka, P; Maiba, J; CASSIDY, R; Chalabi, Z; BORGHI, J;

2023

. Abstract accepted for oral presentation (2023).

Characterising information gains and losses when collecting multiple epidemic model outputs.

Sherratt, K; Srivastava, A; Ainslie, K; Singh, D; Cublier, A; Marinescu, MC; Carretero, J; Cascajo Garcia, A; Franco, N; Willem, L; Abrams, S; Faes, C; Beutels, P; Hens, N; Müller, S; Charlton, B; Ewert, R; Paltra, S; Rakow, C; Rehmann, J; Conrad, T; Schütte, C; Nagel, K; ABBOTT, S; Grah, R; ... FUNK, S.

2023

medRxiv (2023). 10.1101/2023.07.05.23292245.

Longitudinal social contact data analysis: insights from 2 years of data collection in Belgium during the COVID-19 pandemic.

Loedy, N; Coletti, P; Wambua, J; Hermans, L; Willem, L; JARVIS, CI; Wong, KL M; EDMUNDS, WJ; ROBERT, A; Leclerc, QJ; Gimma, A; Molenberghs, G; Beutels, P; Faes, C; Hens, N;

2023

BMC public health, (2023).23 1 10.1186/s12889-023-16193-7.

Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.

Fleming, JA; Baral, R; Higgins, D; Khan, S; Kochar, S; Li, Y; Ortiz, JR; Cherian, T; Feikin, D; JIT, M; Karron, RA; Limaye, RJ; Marshall, C; Munywoki, PK; Nair, H; Newhouse, LC; Nyawanda, BO; Pecenka, C; Regan, K; Srikantiah, P; Wittenauer, R; Zar, HJ; Sparrow, E;

2023

Vaccine, (2023).41 Sup, 10.1016/j.vaccine.2022.09.081.

Outbreak risks, cases, and costs of vaccination strategies against wild poliomyelitis in polio-free settings: a modelling study.

AUZENBERGS, M; Abbas, K; Voorman, A; Peak, C; JIT, M; O'Reilly, K;

2023

medRxiv (2023). 10.1101/2023.07.05.23292288.

Global and regional burden of attributable and associated bacterial antimicrobial resistance avertable by vaccination: modelling study.

KIM, C; Holm, M; Frost, I; Hasso-Agopsowicz, M; ABBAS, K;

2023

BMJ global health, (2023).8 7 10.1136/bmjgh-2022-011341.

The Full Value of Vaccine Assessments (FVVA): a framework for assessing and communicating the value of vaccines for investment and introduction decision-making.

Hutubessy, R; Lauer, JA; Giersing, B; Sim, SY; JIT, M; Kaslow, D; Botwright, S;